BIND Presents Data Demonstrating Ability of Accurins to Improve Efficacy and Tolerability of Multiple Anti-Cancer Agents

By: via Benzinga
BIND Therapeutics, Inc. (NASDAQ: BIND) today reported data demonstrating the efficacy and tolerability of BIND's ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.